Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HEALTHCARE (NY:XLV)

143.21 -0.98 (-0.68%)
Streaming Delayed Price Updated: 12:46 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
38 39 Next >
Stocks At A Major Crossroads. This Chart Is The Key.
A look at the current five most important charts. 
Via Talk Markets
Blame Apple And Microsoft For Dragging Down S&P 500?
Tech giants Apple and Microsoft declined in August on weak revenue guidance, but Federal Reserve rate hikes are also playing a role in a broad-market pullback. 
Via MarketBeat
Topics Economy Stocks
Healthcare Portfolio: A Mixed Market Looking for Value
Many healthcare stocks may be defensive in nature but if you are overweight the basic plays like the XLV or biotech funds like the Fidelity Biotechnology Fund you are trailing the market over the past... 
Via Talk Markets
The 3 Most Promising Healthcare Stocks to Own Now
These top healthcare stock picks are growing revenues by over 30% due to their game-changing medical device products. 
Via InvestorPlace
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects. 
Via MarketBeat
Topics Economy
Bonds Over Earnings?
Via Talk Markets
Developing Your Uniqueness As A Trader
Via Talk Markets
Does A 7.6% Dividend Make Walgreens A Better Buy Than CVS?
These two high-potential healthcare names bring a rare opportunity for investors to gain some exposure to quality businesses trading at a discount to industry 
Via MarketBeat
Protect Your Portfolio and Rotate Into Healthcare Stocks Now
Healthcare stocks are starting to outperform as tech stocks start to falter. Making a rotation now can help you survive what's to come. 
Via InvestorPlace
Energy Holds Above Their 50-DMAs
This month has seen a material decline in the percentage of stocks trading above their respective 50-DMAs. 
Via Talk Markets
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
Beyond The Hustle: Embracing Ancient Chinese Wisdom To Combat Modern Day Burnout
In our modern, high-speed society, many find themselves exhausted in the relentless chase for achievement. Yet, a concept from ancient China that dates back 2,000 years might offer a path to... 
Via Benzinga
Your Mid-August Market Update: Selling And Scanning
Stock indexes slid 1% today with bonds closing weaker, down at 2023 lows as interest rates traded up to highs in 2023. 
Via Talk Markets
Topics Bonds
US Retail Sales Accelerate, On Track For The Best Streak In Over A Year: Sector ETFs To Watch
 
Via Benzinga
Topics ETFs
Buy Merck (MRK) Stock Now to Ride a Wave Higher in Healthcare
Healthcare stocks are starting to shine in 2023 after bottoming out and MRK stock is particularly appealing. Here's why. 
Via InvestorPlace
Investors Go Into Risk-Off Mode For The Fund-Flows Week
Investors were net purchasers of fund assets (including those of conventional funds and ETFs) for the third week in four, injecting a net $10.8 billion. 
Via Talk Markets
Buckle Up! 3 Healthcare Stocks Set to Soar to New Heights
Individual healthcare stocks have been trading really well, even as the sector is treading water. Here are three to know about now. 
Via InvestorPlace
The Good, The Flat, And The Volatile: Sorting Through The Sideways Market
Via Talk Markets
Key ETF Performance Through July 2023
The S&P 500-tracking ETF finished July up 3.27%, leaving it up 20.62% YTD on a total return basis. 
Via Talk Markets
Here's Exactly How I'll Make Over $18,000 in Dividend Income This Year
Even investments with lower yields can generate significant dividend income. 
Via The Motley Fool
Tech Stocks Still Lead Market By Wide Margin This Year
This year’s rally in US stocks continues to rely heavily on a handful of red-hot sectors, based on a review of ETFs. 
Via Talk Markets
Pandemic Shadows Lift As US Consumer Confidence Soars To 2-Year High
 
Via Benzinga
Big Weeks Ahead For MedTech And Life Science Stocks
It’s a big week for earnings that may change the trajectory of the rally but more than likely will continue the rotation into different sectors. 
Via Talk Markets
Jefferies Financial, Apollo Global Management And A Major Sector ETF: CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Shannon Saccocia of NB Private Wealth said to watch for the health-care sector, naming Health Care Select Sector SPDR Fund (NYSE: XLV) 
Via Benzinga
Correction Bottom Searching
Big picture, that‘s what we can expect in stocks over the coming weeks, making for a traders‘ market as select sectors are more richly valued than others. 
Via Talk Markets
Playbook Revisited As UNH Beat Could Help Sagging Healthcare Stocks
Last week saw a broadening of the rally as many top sectors were up over 3%. But healthcare was among the laggards up only 0.7%. 
Via Talk Markets
2023 Midyear Review Of Index ETFs And Smart Beta Strategies & A Tribute To Harry Markowitz
A review and analysis of the first 6 months of 2023 using benchmark ETFs, Sector ETFs, and Smart Beta ETFs and what is likely to follow next. 
Via Talk Markets
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi
Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout. 
Via MarketBeat
Thoughts For Thursday: Back From The Holiday With Caution
Caution is perhaps what was reflected in yesterday's back from the holiday trading. One there is the question of upcoming Fed action and second there is the visit of Secretary Yellen to China. 
Via Talk Markets
$1 Billion Deal For Moderna To Expand Product Pipeline in China
Moderna is looking to diversify its falling U.S. product line, a $1 billion investment in China may act as the catalyst pushing the company's valuation higher 
Via MarketBeat
Topics ETFs Economy
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
38 39 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.